2018 American Transplant Congress
Viral-Specific Cytotoxic T-Cell (Viral-Tc) Responses in Highly-HLA-Sensitized Patients (HS) Maintained on Tacrolimus and Everolimus Post-HLAi Kidney Transplant
Introduction: Viral infections represent significant infectious complications post- kidney transplant which may be increased with desensitization. CMV, EBV and BKV infections are the most prevalent.…2018 American Transplant Congress
CMV and BKV Infections after Kidney Transplantation: Combined Tacrolimus/everolimus Strategy Using Antithymocyte Globulin Induction
Cytomegalovirus (CMV) and BK Virus (BKV) infections are frequent complications after kidney transplantation. A combined regimen of calcineurin inhibitor (CNI) and mTOR inhibitors (mTORi) reduces…2018 American Transplant Congress
Altered Function of Cytomegalovirus Specific T Cells in Transplant Recipients
1Stanford U, Stanford, CA; 2U Pennsylvania, Philadelphia, PA; 3VA Palo Alto, Palo Alto, CA.
Background: Cytomegalovirus (CMV) reactivation is associated with increased morbidity and mortality in transplant recipients. CMV establishes latency for the host's lifetime and frequently reactivates. Immunosuppression,…2018 American Transplant Congress
Clinical Significance of Tacrolimus Trough Level at the Early Period after Kidney Transplantation
Background:The stable immunosuppressant level at the early period after kidney transplantation (KT) is one of the most important factors to decide the prognosis of KT.…2018 American Transplant Congress
The TRANSFORM Study: Infection Outcomes with Everolimus Plus Reduced Calcineurin Inhibitor and Mycophenolate Plus Standard Calcineurin Inhibitor Regimens in De Novo Kidney Transplant Recipients
TRANSFORM Study Group, Novartis Pharma AG, Basel, Switzerland.
Purpose: Post-transplant (Tx) bacterial and viral infections are known to affect graft and patient survival. Accumulating evidence supports the protective effect of everolimus (EVR) against…2018 American Transplant Congress
Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients is Associated with Prolonged Cold Ischemic Time of Seropositive Donor Organs
Introduction: Human Cytomegalovirus (CMV) infection is still a major risk factor for immunocompromised patients, e.g. kidney recipients. Based on the CMV serostatus of donor (D)…2018 American Transplant Congress
Clinical Utility of CMV-Specific CD8+ T-Cell Immune Competence Score in Lung and Heart-Lung Transplant Recipients at Risk of Cytomegalovirus Infection
Introduction: Cytomegalovirus (CMV) is a common infection that causes significant morbidity among lung and heart-lung (LHL) transplant recipients. We determined the clinical utility of global…2018 American Transplant Congress
Cytomegalovirus (CMV) Infection in Small Intestinal and Multivisceral Transplant Recipients: The Role of Donor Selection on CMV Incidence and Outcomes
Medstar Georgetown University Hospital, Washington DC.
Introduction: CMV infection remains an important cause of morbidity, allograft enteritis, and allograft loss in small intestinal (SIT) and multivisceral transplant (MVT) recipients. As the…2018 American Transplant Congress
Standard- versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients
Henry Ford Hospital, Detroit, MI.
Background: Although guidelines recommend valganciclovir (VGC) 900 mg daily for cytomegalovirus (CMV) prophylaxis in solid organ transplant patients, multiple centers have reported clinical success, reduced…2018 American Transplant Congress
Identifying Specificity Groups in the CMV IE-1 T Cell Receptor Repertoire
Cytomegalovirus (CMV) continues to be a major problem for organ transplant recipients. T cells specific to the CMV antigens immediate-early (IE-1) and pp65 CMV govern…
American Transplant Congress abstracts